Role of Thoracoscopic Lung Biopsy by Electrocautery in the Diagnosis of Patients with Diffuse Lung Disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202509649194671

Enrollment

Registered

2025-09-22

Start date

2023-03-14

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory

Interventions

Thoracoscopic Lung Biopsy by Electrocautery

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with a suspected diagnosis of diffuse lung disease aged 18 years or older, patients with undiagnosed diffuse parenchymal lung diseases by clinical, laboratory, and radiological assessment,

Exclusion criteria

Exclusion criteria: patients with a known contraindication to the procedure, such as a bleeding disorder or a severe respiratory condition, patients who had thoracoscopic lung biopsy for therapeutic purposes, rather than diagnostic purposes, patients with a known allergy to any of the medications or materials used during the procedure, patients with coagulopathy, cystic lung diseases, single lung, severe pulmonary hypertension.

Design outcomes

Primary

Measure	Time frame
Successful biopsy acquisition, procedure-related complications, and histological diagnosis.	—

Secondary

Measure	Time frame
Chest Tube Duration, Post-operative Length of Hospital Stay (LOS)	—

Countries

Egypt

Contacts

Public ContactYassin Galal

Assistant lecturer of chest Diseases Al Azhar University assiut

dryassenalazhar@gmail.com+201147293936

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026